CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for
-Expanded collaboration supports development of a second corrector, VX-661, and accelerated discovery and development of next-generation correctors- -Phase 2 study of VX-661 planned for 2011 in people with CF who have the F508del mutation- CAMBRIDGE, Mass.
- Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties - - Global collaboration includes ENTR-701, Entrada’s EEV-investigational candidate for the treatment of DM1 - BOSTON --(BUSINESS WIRE)--Dec.
Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines BOSTON & OXFORD, United Kingdom --(BUSINESS WIRE)--Aug. 30, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a
-Multi-year collaboration leveraging Kymera’s proprietary targeted protein degradation platform to develop novel medicines- -Kymera to receive $70 million upfront, including equity investment, and potential additional milestone and royalty payments for up to six programs in the collaboration-
- Following positive Phase 1/2 results in Vertex’s VX-880 program, Vertex and Lonza announce strategic manufacturing collaboration - - Dedicated large-scale facility will support commercial production of Vertex’s T1D cell therapy portfolio - - Approximately 300 new jobs anticipated at Lonza
Vertex to use Mammoth’s proprietary ultra-small CRISPR systems to discover and develop novel in vivo gene-editing therapies BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Mammoth Biosciences , a biotech company building the next generation
Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Whitehouse Station, NJ and Cambridge, MA, January 6, 2005 -- Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have begun a Phase I
Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Whitehouse Station, NJ and Cambridge, MA, June 17, 2005 - Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of an additional Phase I
-Collaboration to explore use of mRNA Therapeutics to treat the underlying cause of CF by enabling cells to produce functional CFTR proteins in the lungs- - Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with potential